Cancer-Therapy-Related Adverse Events in Organs
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".
Deadline for manuscript submissions: 31 October 2024 | Viewed by 4750
Special Issue Editors
Interests: cancer immunotherapy related GI toxicity; colitis; inflammatory bowel disease; fecal microbiota transplantation
Special Issue Information
Dear Colleagues,
We invite you to contribute to this Special Issue on cancer-therapy-related adverse events in different organ systems. With new cancer treatment strategies emerging rapidly, we recognize the limitations and the need for expanding upon our knowledge of toxicity management. These hurdles frequently disrupt cancer treatments and compromise patients’ outcomes. There is a critical knowledge gap in current clinical practices that needs to be bridged by research data to help practitioners and patients improve their quality of care and outcome.
This Special Issue aims to cover the various organ toxicities related to cancer therapies in the current era. This Special Issue will help to facilitate optimization in the clinical management of cancer care and to reduce symptom burden due to adverse events for cancer populations.
Original research articles and reviews are welcome in this Special Issue. Research areas may include (but are not limited to) cancer-therapy-related adverse events in different organs from one or more of the following categories.
- Toxicity topic
- Cardiology
- Dermatology
- Endocrinology
- Gastroenterology
- Hematology
- Hepatology
- Nephrology
- Neurology
- Ophthalmology
- Pancreatology
- Pulmonology
- Rheumatology
Dr. Yinghong Wang
Dr. Pauline Funchain
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- cancer
- cancer therapy
- toxicities
- adverse events
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.